In the last trading session, 1.23 million Cardiff Oncology Inc (NASDAQ:CRDF) shares changed hands as the company’s beta touched 1.79. With the company’s per share price at $2.55 changed hands at -$0.14 or -5.20% during last session, the market valuation stood at $169.64M. CRDF’s last price was a discount, traded about -145.88% off its 52-week high of $6.27. The share price had its 52-week low at $2.01, which suggests the last value was 21.18% up since then. When we look at Cardiff Oncology Inc’s average trading volume, we note the 10-day average is 1.37 million shares, with the 3-month average coming to 1.12 million.
Analysts gave the Cardiff Oncology Inc (CRDF) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRDF as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Cardiff Oncology Inc’s EPS for the current quarter is expected to be -0.2.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF was in red as seen at the end of in last trading. With action -16.67%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -41.24%, with the 5-day performance at -16.67% in the red. However, in the 30-day time frame, Cardiff Oncology Inc (NASDAQ:CRDF) is -33.59% down. Looking at the short shares, we see there were 13.34 million shares sold at short interest cover period of 11.41 days.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Year-over-year growth is forecast to reach -58.17% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 75k. 7 analysts are of the opinion that Cardiff Oncology Inc’s revenue for the current quarter will be 75k. The company’s revenue for the corresponding quarters a year ago was 205k and 163k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -63.41%. The estimates for the next quarter sales put growth at -53.99%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.36%. The 2025 estimates are for Cardiff Oncology Inc earnings to increase by 13.41%, but the outlook for the next 5-year period is at -9.85% per year.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.62% of Cardiff Oncology Inc shares while 39.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 41.35%. There are 39.03% institutions holding the Cardiff Oncology Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.8637% of the shares, roughly 2.63 million CRDF shares worth $5.84 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.7816% or 2.14 million shares worth $4.74 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.25 shares estimated at $3.2 million under it, the former controlled 1.89% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.63% of the shares, roughly 1.08 shares worth around $2.76 million.
